| Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care |
|
Transplantation and Cellular Therapy |
Myelodysplastic Syndromes (MDS) |
| Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes? |
|
Lancet |
Myelodysplastic Syndromes (MDS) |
| Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial |
|
Lancet |
Myelodysplastic Syndromes (MDS) |
| Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Novel targeted C3 inhibitor pegcetacoplan for paroxysmal nocturnal hemoglobinuria |
|
Clinical and Experimental Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress |
|
Expert Review of Anticancer Therapies |
Myelodysplastic Syndromes (MDS) |
| Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes |
|
European Journal of Haematology |
Myelodysplastic Syndromes (MDS) |
| Considerations for Drug Development in Myelodysplastic Syndromes |
|
Clinical Cancer Research |
Myelodysplastic Syndromes (MDS) |
